Tapinarof

Tapinarof
Clinical data
Trade names	Vtama, others
Other names	Benvitimod; GSK-2894512; (E)-3,5-Dihydroxy-4-isopropyl-trans-stilbene; 3,5-Dihydroxy-4-isopropylstilbene
License data	US DailyMed: Tapinarof;
Routes of; administration	Topical
Drug class	Aryl hydrocarbon receptor agonist
ATC code	D05AX07 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Identifiers
	IUPAC name 5-[(E)-2-Phenylethen-1-yl]-2-(propan-2-yl)benzene-1,3-diol;
CAS Number	79338-84-4;
PubChem CID	6439522;
DrugBank	DB06083;
ChemSpider	4943924;
UNII	84HW7D0V04;
KEGG	D11365;
ChEMBL	ChEMBL259571;
CompTox Dashboard (EPA)	DTXSID301045262 ;
Chemical and physical data
Formula	C17H18O2
Molar mass	254.329 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)c1c(cc(cc1O)/C=C/c2ccccc2)O;
	InChI InChI=1S/C17H18O2/c1-12(2)17-15(18)10-14(11-16(17)19)9-8-13-6-4-3-5-7-13/h3-12,18-19H,1-2H3/b9-8+; Key:ZISJNXNHJRQYJO-CMDGGOBGSA-N;

Tapinarof, also known as benvitimod and sold under the brand name Vtama among others, is a medication used for the treatment of plaque psoriasis. The medication is applied to the skin. Besides its use in medicine, tapinarof is a naturally occurring compound found in bacterial symbionts of nematodes which has antibiotic properties.

The medication acts as an aryl hydrocarbon receptor agonist.

Tapinarof was approved for medical use in the United States in May 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.